Department of Biomedical Engineering, University of Minnesota, Minneapolis, MN 55455, USA.
Adv Mater. 2012 Jul 24;24(28):3803-22, 3710. doi: 10.1002/adma.201200832. Epub 2012 Jun 5.
Encapsulating anticancer drugs in nanoparticles has proven to be an effective mechanism to alter the pharmacokinetic and pharmacodynamic profiles of the drugs, leading to clinically useful cancer therapeutics like Doxil and DaunoXome. Underdeveloped tumor vasculature and lymphatics allow these first-generation nanoparticles to passively accumulate within the tumor, but work to create the next-generation nanoparticles that actively participate in the tumor targeting process is underway. Lipid nanoparticles functionalized with targeting peptides are among the most often studied. The goal of this article is to review the recently published literature of targeted nanoparticles to highlight successful designs that improved in vivo tumor therapy, and to discuss the current challenges of designing these nanoparticles for effective in vivo performance.
将抗癌药物封装在纳米颗粒中已被证明是一种有效的手段，可以改变药物的药代动力学和药效学特性，从而产生像多柔比星脂质体（Doxil）和盐酸柔红霉素脂质体（DaunoXome）这样具有临床应用价值的癌症治疗药物。未充分发育的肿瘤血管和淋巴管使得第一代纳米颗粒能够被动地在肿瘤内积累，但目前正在努力开发能够主动参与肿瘤靶向过程的下一代纳米颗粒。用靶向肽功能化的脂质纳米颗粒是研究最多的纳米颗粒之一。本文的目的是综述最近发表的靶向纳米颗粒的文献，重点介绍那些改善体内肿瘤治疗效果的成功设计，并讨论设计这些纳米颗粒以实现有效体内性能所面临的当前挑战。
